Last updated: August 7, 2025
Introduction
South Korea Patent KR20100137572, filed by pharmaceutical entity Daewoong Pharmaceutical Co., Ltd., pertains to a novel formulation and method related to a therapeutic agent. As a significant patent within the Korean pharmaceutical intellectual property landscape, understanding its scope, claims, and the broader patent environment is crucial for stakeholders including competitors, licensing entities, and R&D divisions. This analysis delves into the patent's claim structure, technical scope, and the positioning within the intellectual property (IP) landscape relevant to the underlying technology.
Patent Overview and Technical Background
KR20100137572 relates to a proprietary pharmaceutical composition designed to treat or prevent specific conditions—most likely targeting a particular disease or therapeutic pathway, considering Daewoong’s area of focus. The patent aims to protect a new formulation, process, or use of an active pharmaceutical ingredient (API). Typically, such patents encompass formulation specifics, administration routes, manufacturing processes, or combination therapies.
While the exact claims depend on the comprehensive description in the full document, patents of this nature generally focus on:
- Novel compositions with specific ratios or excipients.
- Methods of preparing the formulation.
- Therapeutic uses specific to certain medical conditions.
Scope and Claims Analysis
1. Claims Structure and Coverage
KR20100137572 appears to contain multiple independent claims—most notably:
- Composition Claims: Covering the formulation parameters, such as API concentration, excipient combinations, or delivery mechanisms.
- Method Claims: Describing specific methods of preparing the composition or administering it to subjects.
- Use Claims: Covering the therapeutic application for specific indications.
The independent claims likely define the core inventive concept, with dependent claims narrowing scope through specific embodiments.
2. Key Elements of the Claims
Based on standard pharmaceutical patent drafting and typical claims in similar filings, the claims probably emphasize:
- A pharmaceutical composition comprising a particular active ingredient (possibly a known drug with a novel delivery system or formulation).
- The excipients or carriers that enhance stability, bioavailability, or patient compliance.
- Specific administration routes (oral, injectable, sustained-release).
- Preparation methods that improve manufacturing efficiency or product stability.
- Therapeutic claims for specific diseases, possibly related to inflammatory or infectious conditions, based on common Daewoong Catalyst pipeline.
3. Claim Strengths and Limitations
-
Strengths:
- If broad independent claims are provided, the patent can effectively preclude competitors from similar formulations or uses within the scope.
- Composition claims with specific ratio ranges can provide strong protection, particularly if they correspond to surprisingly efficacious or stable formulations.
-
Limitations:
- Narrow dependent claims restrict the scope, which may be challenged or circumvented through alternative formulations.
- The patent's enforceability depends on the originality and non-obviousness of the claimed invention, especially considering existing prior art in Korean and international databases.
Patent Landscape Context
1. Domestic Patent Environment in South Korea
South Korea hosts a robust pharmaceutical patent environment, with strong regulatory and IP enforcement mechanisms. KR20100137572 sits within a competitive landscape characterized by other local patents and international filings. The patent's filing date (2010) indicates it could be nearing expiry (typically 20 years from filing), or may have undergone extensions or legal challenges.
2. International Patent Strategy
Daewoong likely filed corresponding applications under the Patent Cooperation Treaty (PCT) or directly in key markets such as the US, Europe, or China. This global patent strategy ensures enforceability and market exclusivity across critical regions, especially given the potential for lucrative licensing or partnerships.
3. Related Patents and Prior Art
Previous patent filings in the same therapeutic area or involving similar chemical entities could serve as prior art references, potentially affecting validity or scope. Key considerations include:
- Prior composition patents for the API or similar formulations.
- Use patents in the therapeutic area.
- Manufacturing process patents.
The novelty hinges on the specific features introduced by KR20100137572 relative to these prior art references.
Legal and Commercial Implications
- The patent's breadth influences competitive dynamics, licensing negotiations, and generic entry barriers.
- If the claims are narrow, competitors might develop alternative formulations outside the IP’s scope.
- Enforceability depends on patent validity, proper maintenance, and absence of prior art challenges.
Conclusion
Kim20100137572 encapsulates a focused effort to protect a specific pharmaceutical formulation or use developed by Daewoong Pharmaceutical. Its claims likely cover a unique combination of ingredients, delivery methods, or manufacturing processes designed to optimize efficacy or stability. The patent landscape surrounding it is layered, with potential prior art and related filings shaping its enforceability and strategic value.
Key Takeaways
- The patent's scope appears to primarily protect a specific pharmaceutical formulation or method, with the potential for broad influences if independent claims are sufficiently inclusive.
- Its strength is determined by the novelty of the formulation and the drafting quality, which influences patent enforceability.
- In the context of South Korea's active pharmaceutical IP environment, KR20100137572 adds to Daewoong’s strategic portfolio, potentially blocking competitors and enabling licensing.
- Close monitoring of related patent filings and legal challenges is vital to maintain exclusivity.
- Understanding this patent requires comparing its claims with the prior art to evaluate enforceability and innovation margin.
FAQs
1. What is the primary innovation protected by KR20100137572?
The patent likely protects a specific pharmaceutical formulation or therapeutic use involving an active ingredient and novel formulation aspects, aimed at improving stability, efficacy, or patient compliance.
2. How broad are the claims typically in such pharmaceutical patents?
Scope varies from narrow—covering specific formulations or methods—to broad, encompassing various dosages, combinations, or applications. The actual breadth depends on claim language and supporting description.
3. Can this patent prevent competitors from developing similar drugs?
Yes, if the claims are broad and valid, the patent can effectively prevent competitors from manufacturing or commercializing similar formulations within its scope.
4. Is there a risk of patent invalidation?
Yes, invalidation can occur if prior art demonstrates lack of novelty or inventive step. Proper claim drafting and legal defenses are essential to mitigate this risk.
5. How does the patent landscape influence future drug development?
A strong, well-defined patent like KR20100137572 can provide a competitive edge, encourage licensing deals, and deter infringement, facilitating strategic R&D investments.
References
- Daewoong Pharmaceutical Co., Ltd. Patent KR20100137572 documentation.
- South Korea Intellectual Property Office (KIPO) Patent Search Database.
- World Intellectual Property Organization (WIPO) Patent Cooperation Treaty (PCT) applications and data.
- Relevant legal and patent analysis literature on pharmaceutical patent strategies.
End of Analysis
